IL145406A0 - Melanocortin receptor ligands - Google Patents

Melanocortin receptor ligands

Info

Publication number: IL145406A0
Authority: IL; Israel
Prior art keywords: receptor ligands; melanocortin receptor; melanocortin; ligands; receptor
Prior art date: 1999-03-29

Application number

IL14540600A

Other languages

English (en)

Original Assignee

Procter & Gamble

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-29

Filing date

2000-03-21

Publication date

2002-06-30

2000-03-21 Application filed by Procter & Gamble filed Critical Procter & Gamble

2002-06-30 Publication of IL145406A0 publication Critical patent/IL145406A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)

IL14540600A 1999-03-29 2000-03-21 Melanocortin receptor ligands IL145406A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12667399P	1999-03-29	1999-03-29
PCT/US2000/007473 WO2000058361A1 (en)	1999-03-29	2000-03-21	Melanocortin receptor ligands

Publications (1)

Publication Number	Publication Date
IL145406A0 true IL145406A0 (en)	2002-06-30

Family

ID=22426131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14540600A IL145406A0 (en)	1999-03-29	2000-03-21	Melanocortin receptor ligands

Country Status (34)

Country	Link
US (2)	US6613874B1 (es)
EP (1)	EP1165613B1 (es)
JP (1)	JP2002542159A (es)
KR (2)	KR100558131B1 (es)
CN (1)	CN1249086C (es)
AR (1)	AR023201A1 (es)
AT (1)	ATE393783T1 (es)
AU (1)	AU763510B2 (es)
BR (1)	BR0009497A (es)
CA (1)	CA2368431C (es)
CO (1)	CO5170531A1 (es)
CZ (1)	CZ20013407A3 (es)
DE (1)	DE60038734T2 (es)
DK (1)	DK1165613T3 (es)
ES (1)	ES2304345T3 (es)
HK (1)	HK1044954B (es)
HU (1)	HUP0202203A3 (es)
ID (1)	ID30262A (es)
IL (1)	IL145406A0 (es)
MA (1)	MA25403A1 (es)
MX (1)	MXPA01009881A (es)
MY (1)	MY126585A (es)
NO (1)	NO20014568L (es)
NZ (1)	NZ514141A (es)
PE (1)	PE20001641A1 (es)
PL (1)	PL350095A1 (es)
PT (1)	PT1165613E (es)
RU (1)	RU2213098C2 (es)
SA (1)	SA00210192B1 (es)
SK (1)	SK13082001A3 (es)
TR (1)	TR200102765T2 (es)
TW (1)	TWI250990B (es)
WO (1)	WO2000058361A1 (es)
ZA (1)	ZA200107411B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7192713B1 (en)	1999-05-18	2007-03-20	President And Fellows Of Harvard College	Stabilized compounds having secondary structure motifs
WO2000074679A1 (en)	1999-06-04	2000-12-14	Merck & Co., Inc.	Substituted piperidines as melanocortin-4 receptor agonists
US7235625B2 (en)	1999-06-29	2007-06-26	Palatin Technologies, Inc.	Multiple agent therapy for sexual dysfunction
EP1251865A1 (en) *	2000-01-18	2002-10-30	Merck & Co., Inc.	Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
HUP0303078A3 (en)	2000-08-30	2012-02-28	Hoffmann La Roche	Cyclic peptidies process for their preparation pharmaceutical compositions containing them and their use
EP1409540A2 (en) *	2000-09-27	2004-04-21	The Procter & Gamble Company	Melanocortin receptor ligands
AU2002238106A1 (en)	2001-02-13	2002-08-28	Palatin Technologies, Inc.	Melanocortin metallopeptides for treatment of sexual dysfunction
US7345144B2 (en) *	2001-07-11	2008-03-18	Palatin Technologies, Inc.	Cyclic peptides for treatment of cachexia
US7342089B2 (en) *	2001-07-11	2008-03-11	Palatin Technologies, Inc.	Cyclic peptides for treatment for cachexia
IL159797A0 (en)	2001-07-11	2004-06-20	Palatin Technologies Inc	Linear and cyclic melanocortin receptor-specific peptides
US20030195187A1 (en) *	2002-02-04	2003-10-16	Chiron Corporation	Guanidino compounds
US7034004B2 (en) *	2002-05-07	2006-04-25	University Of Florida	Peptides and methods for the control of obesity
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
US20070105759A1 (en) *	2003-06-19	2007-05-10	Eli Lilly And Company	Melanocortin receptor 4 (mc4) agonists and their uses
US20060293223A1 (en) *	2003-06-19	2006-12-28	Eli Lilly And Company Patent Division	Uses of melanocortin-3 receptor (mc3r) agonist peptides
MXPA06003474A (es) *	2003-09-30	2006-06-05	Novo Nordisk As	Agonistas de receptores de melanocortina.
AU2015201062B2 (en) *	2003-11-05	2017-03-09	Dana-Farber Cancer Institute, Inc.	Stabilized alpha helical peptides and uses thereof
SI1680443T1 (sl) *	2003-11-05	2014-01-31	Dana-Farber Cancer Institute, Inc.	Stabilizirani peptidi z alfa vijačnico in uporabe le-teh
EP2368579A1 (en)	2004-01-21	2011-09-28	Novo Nordisk Health Care AG	Transglutaminase mediated conjugation of peptides
US6974187B2 (en) *	2004-01-28	2005-12-13	Tachi-S Co., Ltd.	Vehicle seat structure
CA2557739A1 (en) *	2004-03-29	2005-11-03	Eli Lilly And Company	Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
US20080021067A1 (en) *	2004-10-05	2008-01-24	Linda Bristow	Methods For The Treatment Of Substance Abuse And Addiction
WO2006060873A1 (en) *	2004-12-09	2006-06-15	Prince Henry's Institute Of Medical Research	Method for restoring reproductive function
WO2006073772A1 (en) *	2005-01-05	2006-07-13	Eli Lilly And Company	Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073771A2 (en) *	2005-01-05	2006-07-13	Eli Lilly And Company	Polyethylene glycol linked mc4r or mc3r agonist peptides
US20070021433A1 (en)	2005-06-03	2007-01-25	Jian-Qiang Fan	Pharmacological chaperones for treating obesity
US7754691B1 (en)	2005-07-07	2010-07-13	Palatin Technologies, Inc.	Linear melanocortin receptor-specific peptides for cachexia
EP3925614A3 (en)	2005-07-08	2022-03-23	Ipsen Pharma	Melanocortin receptor ligands
CA2614678A1 (en)	2005-07-08	2007-01-18	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Ligands of melanocortin receptors
EP1968995A1 (en) *	2005-12-30	2008-09-17	F. Hoffmann-la Roche AG	Methods for the synthesis of arginine-containing peptides
HUE029016T2 (en)	2006-06-09	2017-02-28	Synact Pharma Aps	Phenylpyrrolidinoguanidine derivatives
US7981998B2 (en)	2006-12-14	2011-07-19	Aileron Therapeutics, Inc.	Bis-sulfhydryl macrocyclization systems
EP3170835A1 (en)	2006-12-14	2017-05-24	Aileron Therapeutics, Inc.	Bis-sulfhydryl macrocyclization systems
DK2118123T3 (en)	2007-01-31	2016-01-25	Dana Farber Cancer Inst Inc	Stabilized p53 peptides and uses thereof
EP2114428B1 (en) *	2007-02-23	2012-10-31	Aileron Therapeutics, Inc.	Triazole linked macrocyclic peptides
EP3159352B1 (en)	2007-03-28	2023-08-02	President and Fellows of Harvard College	Stitched polypeptides
CA2689016C (en)	2007-05-25	2014-08-12	Ipsen Pharma S.A.S.	Melanocortin receptor ligands modified with hydantoin
DE112009000300T5 (de)	2008-02-08	2011-01-20	Aileron Therapeutics, Inc., Cambridge	Therapeutische Peptidomimetische Makrocyclen
US20090326192A1 (en) *	2008-04-08	2009-12-31	Aileron Therapeutics, Inc.	Biologically active peptidomimetic macrocycles
US20110144303A1 (en) *	2008-04-08	2011-06-16	Aileron Therapeutics, Inc.	Biologically Active Peptidomimetic Macrocycles
CA2727317C (en)	2008-06-09	2015-02-17	Palatin Technologies, Inc.	Melanocortin receptor-specific peptides for treatment of sexual dysfunction
TW201002340A (en) *	2008-06-09	2010-01-16	Palatin Technologies Inc	Melanocortin receptor-specific peptides for treatment of obesity
US20110144306A1 (en)	2008-07-23	2011-06-16	President And Fellows Of Harvard College	Ligation of stapled polypeptides
CA2737921C (en)	2008-09-22	2019-01-15	Aileron Therapeutics, Inc.	Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels
EP2376100B1 (en)	2009-01-14	2017-10-25	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
EP2440572B1 (en)	2009-06-08	2017-04-05	Palatin Technologies, Inc.	Lactam-bridged melanocortin receptor-specific peptides
NZ596617A (en)	2009-06-08	2014-04-30	Palatin Technologies Inc	Melanocortin receptor-specific peptides
UY32690A (es)	2009-06-08	2011-01-31	Astrazeneca Ab	Péptidos específicos para receptores de melanocortina
EP2453908B1 (en)	2009-07-13	2018-03-14	President and Fellows of Harvard College	Bifunctional stapled polypeptides and uses thereof
CA2774973A1 (en)	2009-09-22	2011-03-31	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
CN102686601A (zh) *	2009-11-16	2012-09-19	益普生制药股份有限公司	合成Ac-Arg-环(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2的方法
MX2012005859A (es)	2009-11-23	2012-12-17	Palatin Technologies Inc	Peptidos lineales especificos del receptor de melanocortina-1.
EP2504352B1 (en)	2009-11-23	2018-11-14	Palatin Technologies, Inc.	Melanocortin-1 receptor-specific cyclic peptides
CN101824415A (zh) *	2010-03-31	2010-09-08	华东师范大学	黑素皮质1型受体基因的snp及其应用
SI2603600T1 (sl)	2010-08-13	2019-04-30	Aileron Therapeutics, Inc.	Peptidomimetični makrocikli
WO2012040459A2 (en)	2010-09-22	2012-03-29	President And Fellows Of Harvard College	Beta-catenin targeting peptides and uses thereof
US9018395B2 (en)	2011-01-27	2015-04-28	Université de Montréal	Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
WO2012174423A1 (en)	2011-06-17	2012-12-20	President And Fellows Of Harvard College	Stabilized polypeptides as regulators of rab gtpase function
EP2768518A4 (en)	2011-10-18	2015-05-27	Aileron Therapeutics Inc	PEPTIDOMIMETIC MACROCYCLES
US8927500B2 (en)	2012-02-15	2015-01-06	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
WO2013123267A1 (en)	2012-02-15	2013-08-22	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
ES2874525T3 (es)	2012-09-26	2021-11-05	Harvard College	Péptidos grapados bloqueados con prolina y usos de los mismos
AU2013337388B2 (en)	2012-11-01	2018-08-02	Aileron Therapeutics, Inc.	Disubstituted amino acids and methods of preparation and use thereof
CN105307667B (zh)	2013-03-13	2019-04-19	哈佛大学的校长及成员们	钉合且缝合的多肽及其用途
KR20160019547A (ko)	2013-06-14	2016-02-19	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	안정화된 폴리펩티드 인슐린 수용체 조절제
AU2015264122B2 (en)	2014-05-21	2021-02-04	President And Fellows Of Harvard College	Ras inhibitory peptides and uses thereof
MX2017003797A (es)	2014-09-24	2017-06-15	Aileron Therapeutics Inc	Macrociclos peptidomimeticos y usos de los mismos.
BR112017005736A2 (pt)	2014-09-24	2017-12-12	Aileron Therapeutics Inc	macrociclos peptidomiméticos e formulações dos mesmos
CN107614003A (zh)	2015-03-20	2018-01-19	艾瑞朗医疗公司	拟肽大环化合物及其用途
WO2017004548A1 (en)	2015-07-01	2017-01-05	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
CN108368161A (zh)	2015-09-10	2018-08-03	艾瑞朗医疗公司	作为mcl-1调节剂的拟肽大环化合物
AU2020273479B2 (en)	2019-05-10	2025-02-27	Synact Pharma Aps	Combination treatment of arthritic disease
CN110681362B (zh) *	2019-09-26	2020-09-11	浙江大学	以羧基和吲哚基为功能基团的混合模式层析介质
US11590209B2 (en)	2020-01-21	2023-02-28	Palatin Technologies, Inc.	Use of bremelanotide in patients with controlled hypertension
US11932628B2 (en)	2021-01-04	2024-03-19	Regents Of The University Of Minnesota	Selective small molecule peptidomimetic melanocortin ligands
EP4684835A2 (en)	2021-06-21	2026-01-28	SynAct Pharma ApS	Phenyl pyrrole aminoguanidine salts and formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5462927A (en)	1985-04-30	1995-10-31	The Administrators Of The Tulane Educational Fund	Peptides aiding nerve regeneration
DE3851002T2 (de)	1987-05-22	1995-02-02	University Patents, Inc., Westport, Conn.	Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
WO1989002897A1 (en)	1987-09-24	1989-04-06	The Administrators Of The Tulane Educational Fund	Therapeutic peptides
ZA908610B (en)	1989-11-03	1991-08-28	Univ Tulane	Peptides aiding nerve regeneration
CA2061246A1 (en)	1991-02-15	1992-08-16	Mitsuhiro Wakimasu	Peptides having antagonistic activities to endothelin receptors, production and use thereof
DE69220861T2 (de)	1991-08-13	1997-11-20	Takeda Chemical Industries Ltd	Zyklische Peptide und ihre Verwendung
RU2096415C1 (ru) *	1991-09-30	1997-11-20	Дзе Дюпон Мерк Фармасьютикал Компани	Циклические пептиды или их фармацевтически приемлемые соли, фармацевтическая композиция
EP0552417B1 (en)	1991-11-19	1999-07-07	Takeda Chemical Industries, Ltd.	Cyclic peptides and use thereof
EP0547317A1 (en)	1991-12-19	1993-06-23	Takeda Chemical Industries, Ltd.	Endothelin antagonists
DE9203901U1 (de)	1992-03-24	1992-07-16	Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen	Gestell zum Lagern von flächigen Werkstücken
AU672426B2 (en)	1992-07-27	1996-10-03	Biomeasure, Inc.	Neuromedin B receptor antagonists
US5569741A (en)	1992-07-27	1996-10-29	Biomeasure, Inc.	Cyclic octapeptide neuromedin B receptor antagonists
AU673731B2 (en)	1993-06-03	1996-11-21	Banyu Pharmaceutical Co., Ltd.	Novel endothelin antagonistic peptide
EP0714909A1 (en)	1994-12-01	1996-06-05	Takeda Chemical Industries, Ltd.	Composition for prophylaxis or treatment of pulmonary circulatory diseases
US6054556A (en) *	1995-04-10	2000-04-25	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Melanocortin receptor antagonists and agonists
US5731408A (en) *	1995-04-10	1998-03-24	Arizona Board Of Regents On Behalf Of The University Of Arizona	Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6136781A (en)	1995-04-28	2000-10-24	Takeda Chemical Industries, Ltd.	LH-RH receptor antagonists
US5817750A (en)	1995-08-28	1998-10-06	La Jolla Cancer Research Foundation	Structural mimics of RGD-binding sites
CA2249439C (en)	1996-06-11	2009-09-08	Novartis Ag	Combination of a somatostatin analogue and a rapamycin
EP0967222A4 (en)	1996-06-25	2001-08-22	Nisshin Flour Milling Co	CYCLIC DEPSIPEPTIDES AND MEDICINES CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENT
EP0815870A3 (en)	1996-06-27	2000-05-03	Takeda Chemical Industries, Ltd.	Composition for prohylaxis or treatment of cerebral infarction
US5770380A (en)	1996-09-13	1998-06-23	University Of Pittsburgh	Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
IT1288388B1 (it)	1996-11-19	1998-09-22	Angeletti P Ist Richerche Bio	Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
JP2001506996A (ja)	1996-12-17	2001-05-29	クアドラントホールディングスケンブリッジリミテッド	メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体
SE9700620D0 (sv) *	1997-02-21	1997-02-21	Wapharm Ab	Cykliska peptider med selektivitet för MSH-receptor subtyper
GB9827500D0 (en)	1998-12-14	1999-02-10	Wapharm Ab	Compounds for control of eating, growth and body weight

2000
- 2000-03-21 AU AU40179/00A patent/AU763510B2/en not_active Ceased
- 2000-03-21 CZ CZ20013407A patent/CZ20013407A3/cs unknown
- 2000-03-21 RU RU2001128890/04A patent/RU2213098C2/ru not_active IP Right Cessation
- 2000-03-21 AT AT00919500T patent/ATE393783T1/de not_active IP Right Cessation
- 2000-03-21 CN CNB008057540A patent/CN1249086C/zh not_active Expired - Fee Related
- 2000-03-21 MX MXPA01009881A patent/MXPA01009881A/es active IP Right Grant
- 2000-03-21 NZ NZ514141A patent/NZ514141A/xx unknown
- 2000-03-21 IL IL14540600A patent/IL145406A0/xx unknown
- 2000-03-21 KR KR1020047019303A patent/KR100558131B1/ko not_active Expired - Fee Related
- 2000-03-21 ID IDW00200102111A patent/ID30262A/id unknown
- 2000-03-21 ES ES00919500T patent/ES2304345T3/es not_active Expired - Lifetime
- 2000-03-21 KR KR10-2001-7012436A patent/KR100519201B1/ko not_active Expired - Fee Related
- 2000-03-21 WO PCT/US2000/007473 patent/WO2000058361A1/en not_active Ceased
- 2000-03-21 PL PL00350095A patent/PL350095A1/xx not_active Application Discontinuation
- 2000-03-21 JP JP2000608653A patent/JP2002542159A/ja active Pending
- 2000-03-21 EP EP00919500A patent/EP1165613B1/en not_active Expired - Lifetime
- 2000-03-21 DE DE60038734T patent/DE60038734T2/de not_active Expired - Fee Related
- 2000-03-21 HU HU0202203A patent/HUP0202203A3/hu unknown
- 2000-03-21 SK SK1308-2001A patent/SK13082001A3/sk unknown
- 2000-03-21 PT PT00919500T patent/PT1165613E/pt unknown
- 2000-03-21 HK HK02104687.8A patent/HK1044954B/en not_active IP Right Cessation
- 2000-03-21 TR TR2001/02765T patent/TR200102765T2/xx unknown
- 2000-03-21 BR BR0009497-8A patent/BR0009497A/pt not_active IP Right Cessation
- 2000-03-21 DK DK00919500T patent/DK1165613T3/da active
- 2000-03-21 CA CA002368431A patent/CA2368431C/en not_active Expired - Fee Related
- 2000-03-27 MY MYPI20001220A patent/MY126585A/en unknown
- 2000-03-28 TW TW089105726A patent/TWI250990B/zh not_active IP Right Cessation
- 2000-03-28 CO CO00022068A patent/CO5170531A1/es not_active Application Discontinuation
- 2000-03-29 US US09/537,789 patent/US6613874B1/en not_active Expired - Fee Related
- 2000-03-29 PE PE2000000267A patent/PE20001641A1/es not_active Application Discontinuation
- 2000-03-29 AR ARP000101405A patent/AR023201A1/es active IP Right Grant
- 2000-06-26 SA SA00210192A patent/SA00210192B1/ar unknown
2001
- 2001-09-07 ZA ZA200107411A patent/ZA200107411B/xx unknown
- 2001-09-20 NO NO20014568A patent/NO20014568L/no not_active Application Discontinuation
- 2001-09-26 MA MA26340A patent/MA25403A1/fr unknown
2003
- 2003-07-02 US US10/612,104 patent/US6951916B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2368431A1 (en)	2000-10-05
ZA200107411B (en)	2002-05-29
ID30262A (id)	2001-11-15
AU4017900A (en)	2000-10-16
RU2213098C2 (ru)	2003-09-27
PT1165613E (pt)	2008-07-29
US20040023859A1 (en)	2004-02-05
JP2002542159A (ja)	2002-12-10
KR20020008143A (ko)	2002-01-29
EP1165613A1 (en)	2002-01-02
NO20014568L (no)	2001-11-29
HUP0202203A3 (en)	2003-09-29
ATE393783T1 (de)	2008-05-15
NO20014568D0 (no)	2001-09-20
MY126585A (en)	2006-10-31
DK1165613T3 (da)	2008-08-25
US6613874B1 (en)	2003-09-02
CZ20013407A3 (cs)	2002-02-13
AU763510B2 (en)	2003-07-24
PE20001641A1 (es)	2001-02-07
MA25403A1 (fr)	2002-04-01
AR023201A1 (es)	2002-09-04
US6951916B2 (en)	2005-10-04
KR100519201B1 (ko)	2005-10-06
KR20050009722A (ko)	2005-01-25
NZ514141A (en)	2004-01-30
HK1044954A1 (en)	2002-11-08
TR200102765T2 (tr)	2002-05-21
CO5170531A1 (es)	2002-06-27
EP1165613B1 (en)	2008-04-30
ES2304345T3 (es)	2008-10-16
MXPA01009881A (es)	2002-05-06
CN1249086C (zh)	2006-04-05
TWI250990B (en)	2006-03-11
HUP0202203A2 (en)	2002-10-28
CA2368431C (en)	2006-01-24
BR0009497A (pt)	2002-01-15
SA00210192B1 (ar)	2006-06-04
HK1044954B (en)	2008-11-21
DE60038734D1 (de)	2008-06-12
CN1345335A (zh)	2002-04-17
SK13082001A3 (sk)	2002-03-05
DE60038734T2 (de)	2009-07-02
PL350095A1 (en)	2002-11-04
KR100558131B1 (ko)	2006-03-10
WO2000058361A1 (en)	2000-10-05

Publication	Publication Date	Title
IL145406A0 (en)	2002-06-30	Melanocortin receptor ligands
GB9808229D0 (en)	1998-06-17	Melanocortin receptor ligands
IL154437A0 (en)	2003-09-17	Melanocortin receptor ligands
IL152781A0 (en)	2003-06-24	Melanocortin receptor ligands
IL157969A0 (en)	2004-03-28	Melanocortin receptor ligands
AU139912S (en)	2000-02-25	Bracket
IL146151A0 (en)	2002-07-25	Human-g-protein receptor
GB9903647D0 (en)	1999-04-07	Mat
PL351279A1 (en)	2003-04-07	Integrin receptor ligands
EP1188760A4 (en)	2002-08-07	IP3 RECEIVER LIGANDS
GB2361278B (en)	2002-04-03	Bracket
GB9928157D0 (en)	2000-01-26	Bracket
GB9922281D0 (en)	1999-11-17	Polymorphism
GB9920046D0 (en)	1999-10-27	Novel receptor/ligand
GB9815373D0 (en)	1998-09-16	Receptor ligands
GB9905079D0 (en)	1999-04-28	Bracket
AU140053S (en)	2000-03-15	Bracket
GB9914884D0 (en)	1999-08-25	Bracket
AU139432S (en)	1999-12-17	Bracket
AU136496S (en)	1999-02-16	Mat
GB9925807D0 (en)	1999-12-29	Mat
PL334827A1 (en)	2001-02-12	Mat
GB9923812D0 (en)	1999-12-08	Ligand design
GB9917155D0 (en)	1999-09-22	Boxguard union bracket
AU138976S (en)	1999-12-01	Place mat